

# Lorenzo Antonuzzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8784088/publications.pdf>

Version: 2024-02-01

13  
papers

92  
citations

1937457

4  
h-index

1588896

8  
g-index

13  
all docs

13  
docs citations

13  
times ranked

34  
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
2	Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. <i>British Journal of Cancer</i> , 2021, 125, 94-100.	2.9	23
3	FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer <i>RAS/BRAF</i> Mutated: Safety Run-In of Phase II NIVACOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 766500.	1.3	12
4	Ivosidenib in <i>IDH1</i> -mutated cholangiocarcinoma: Clinical evaluation and future directions. , 2022, 237, 108170.		9
5	Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study. <i>Clinical Nutrition</i> , 2021, 40, 4980-4987.	2.3	7
6	Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA3505-LBA3505.	0.8	6
7	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The <i>Meet-Uro 19BEYOND</i> study. <i>Cancer Medicine</i> , 2022, 11, 3084-3092.	1.3	4
8	Liquid biopsy in colorectal cancer: No longer young, but not yet old. <i>World Journal of Gastroenterology</i> , 2022, 28, 1503-1507.	1.4	4
9	The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. <i>Immunotherapy</i> , 2022, 14, 567-576.	1.0	2
10	Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study ( <i>Meet-Uro 19</i> ).. <i>Journal of Clinical Oncology</i> , 2021, 39, 319-319.	0.8	1
11	Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	0
12	Weight loss affects outcome in <i>KrasG12C</i> non-small cell lung cancer first line treated patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21054-e21054.	0.8	0
13	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16068-e16068.	0.8	0